CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Lynparza for Newly Diagnosed Ovarian Cancer – Details

Project Number PC0174-000
Brand Name Lynparza
Generic Name Olaparib
Strength 100 mg and 150 mg
Tumour Type Gynecology
Indication Ovarian Cancer
Funding Request As monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy, until disease progression or up to 2 years if no evidence of disease. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.
Review Status Complete
Pre Noc Submission Yes
NOC Date May 6, 2019
Manufacturer AstraZeneca Canada
Sponsor AstraZeneca Canada
Submission Date April 18, 2019
Submission Deemed Complete May 3, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ May 3, 2019
Check-point meeting July 3, 2019
pERC Meeting September 19, 2019
Initial Recommendation Issued October 3, 2019
Feedback Deadline ‡ October 18, 2019
pERC Reconsideration Meeting November 21, 2019
Final Recommendation Issued December 5, 2019
Notification to Implement Issued December 20, 2019
Therapeutic Area Newly Diagnosed OC
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.